• Cyclosporin A as a Translational Mechanism Probe

  2026-08-18

  Cyclosporin A is more than a classic immunosuppressant: it is a pathway-resolved probe spanning cyclophilin–calcineurin–NF-AT signaling, p38 MAPK activity, and mitochondrial permeability transition. This thought-leadership guide shows how translational researchers can use Cyclosporin to distinguish target engagement from downstream phenotype while avoiding overinterpretation across immunology, mitochondrial biology, and neuroscience.

• Mechanisms of Cell Death in Heart Disease

  2026-08-18

  Konstantinidis, Whelan, and Kitsis synthesize evidence showing that cardiac injury involves not only apoptosis and passive necrosis, but also regulated forms of necrotic death connected through overlapping signaling pathways. The review is important for experimental design because it links cell morphology, ATP status, death-receptor signaling, mitochondria, and the endoplasmic reticulum while emphasizing that therapeutic inhibition of cell death requires careful definition of the death mechanism.

• p-Cresyl Sulfate and Aortic Valve Calcification

  2026-08-17

  The reference study identifies p-Cresyl sulfate as a driver of calcification in aortic valvular interstitial cells and connects this effect to HIF-1α activation, klotho loss, NF-κB acetylation, and RUNX2 induction. Its combined porcine-cell and rat CKD-model design supports klotho and SIRT1-linked signaling as experimentally testable targets in calcific aortic valve disease.

• SB-505124 Hydrochloride in Cancer Mechanobiology

  2026-08-17

  SB-505124 hydrochloride provides a reversible way to separate TGF-β/activin signaling from ion channel–regulated cancer cell mechanics. This article presents a practical, multi-readout strategy linking Smad signaling, stiffness, and immune-cell susceptibility without overstating the current evidence.

• ERAD Hijacking for Transmembrane Protein Degradation

  2026-08-16

  The reference study introduces ERAD-engaging chimeras (ERADECs), a targeted protein degradation platform that redirects endoplasmic-reticulum-associated degradation toward transmembrane proteins. Its desonide-based PD-L1 degraders achieved sub-nanomolar activity and stronger tumor suppression than a clinically used PD-L1 antibody in vivo, establishing a mechanistic framework for expanding degradation beyond conventional cytosolic and lysosomal routes.

• Maternal IL-17A and Neonatal GBS Disease Risk

  2026-08-15

  This prospective mother–newborn study links reduced maternal IL-17A responses with invasive Group B Streptococcus disease in newborns. By combining cytokine profiling with ex vivo pathogen-recognition receptor stimulation, it identifies maternal IL-17A as a promising risk-stratification biomarker while highlighting the limits of using colonization status alone.

• TAK1–YAP Signaling in Gastric Cancer Stem Cells

  2026-08-14

  The reference study identifies TGFβ-activated kinase 1 (TAK1) as a regulator of gastric cancer stem-cell self-renewal and oncogenesis. Its proposed mechanism links IL-6–dependent TAK1 elevation to cytoplasmic YAP stabilization and increased SOX2 and SOX9 transcription, providing a mechanistic framework for studying gastric cancer stemness.

• A 83-01 for Biliary Injury Signaling Studies

  2026-08-14

  A 83-01 is an ALK-5 inhibitor that enables mechanistic dissection of TGF-β responses in biliary organoids and injury models. This article connects its pharmacology with new evidence on WNT-dependent extrahepatic bile duct proliferation while defining assay controls, interpretation limits, and practical handling.

• Methylprednisolone Workflows for Inflammation and Bone

  2026-08-13

  Methylprednisolone supports more than routine cytokine testing: it can create controlled glucocorticoid perturbations for macrophage, PBMC, skin-culture, and osteonecrosis workflows. This guide connects solvent handling and assay design with osteoclast, imaging, and tissue-readout strategies.

• Rotigotine in Parkinson’s Disease Research

  2026-08-13

  Learn how to use Rotigotine as a dopamine D2/D3 receptor agonist across SH-SY5Y neuroprotection assays, nanoparticle delivery studies, and animal models of Parkinson’s disease. This workflow emphasizes formulation-aware controls, quantitative oxidative-stress readouts, and troubleshooting for reproducible translational data.

• SB 431542: From Pathway Blockade to Translation

  2026-08-12

  SB 431542 is more than a routine pathway reagent: it is a selective ALK5 inhibitor that can connect receptor-level mechanism with proliferation, invasion, and immune-interaction phenotypes. This thought-leadership guide outlines how translational researchers can use it to interrogate TGF-β biology across glioma, placental, and tumor-immunity models while preserving experimental rigor.

• Calpeptin: A Causal Tool for Cell-Death Assays

  2026-08-12

  Calpeptin is a potent calpain inhibitor for dissecting how calcium-dependent proteolysis intersects with regulated cell death, fibrosis, and inflammation. This article presents an assay-centered framework that connects cardiovascular cell-death biology with pulmonary fibrosis research without overstating translational evidence.

• TRPV1 Nerves in the Somato-Autonomic Reflex

  2026-08-11

  A 2025 iScience study identifies a neural circuit through which stimulation of TRPV1-positive peripheral afferents suppresses systemic inflammation. The work links nape stimulation to brainstem activation, corticosterone and catecholamine release, autonomic control of the spleen, and inflammation-associated transcriptional changes, providing a mechanistic framework for studying somato-autonomic immune regulation.

• L-Phenylephrine in Sex-Aware Adrenergic Research

  2026-08-11

  L-Phenylephrine is more than a vasoconstrictor probe: its α1A preference provides a practical entry point for connecting receptor signaling with sex-dependent cardiovascular physiology, cardiomyocyte survival, neural progenitor responses, and translational airway research.

• Optimizing hiPSC Platelet Differentiation: Study Insights

  2026-08-10

  A 2026 study presents an optimized differentiation scheme that combines higher embryoid body input, human platelet lysate, cytokine-replacing small molecules, and enhanced megakaryocyte polyploidization to improve platelet production from human iPSCs. The protocol shortened production to 19 days, generated 14.9 platelets per iPSC, and reduced reported costs by 58.3%, while retaining measurable platelet function in vitro.

16282 records 1/1086 page Next 12345 下5页 Last page